Rana Anjum

2.5k total citations · 1 hit paper
20 papers, 1.2k citations indexed

About

Rana Anjum is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Rana Anjum has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Rana Anjum's work include Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Rana Anjum is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Rana Anjum collaborates with scholars based in United States, United Kingdom and Japan. Rana Anjum's co-authors include John Blenis, Steven P. Gygi, Bryan A. Ballif, Philippe P. Roux, Andrew R. Tee, Tim Clackson, Victor M. Rivera, Frank Wang, Scott Wardwell and Yaoyu Ning and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Rana Anjum

19 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

2004 611 citations Philippe P. Roux, Bryan A. Ballif et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rana Anjum United States	10	864	259	239	140	116	20	1.2k
Jianhui Cai China	20	541 0.6×	226 0.9×	273 1.1×	39 0.3×	46 0.4×	40	1.1k
Susan C. Evans United States	19	739 0.9×	265 1.0×	88 0.4×	39 0.3×	128 1.1×	28	1.1k
Liwei Wang China	13	616 0.7×	223 0.9×	109 0.5×	46 0.3×	79 0.7×	24	906
Philip M. Hemken United States	10	745 0.9×	188 0.7×	131 0.5×	118 0.8×	90 0.8×	15	1.0k
Birgit Bossenmaier Germany	19	807 0.9×	816 3.2×	180 0.8×	161 1.1×	68 0.6×	42	1.8k
Adam Shutes United States	16	847 1.0×	186 0.7×	81 0.3×	39 0.3×	312 2.7×	19	1.2k
Katsuhiro Anami Japan	18	706 0.8×	372 1.4×	283 1.2×	28 0.2×	77 0.7×	35	1.2k
Silvia Mateo‐Lozano Spain	19	511 0.6×	263 1.0×	308 1.3×	33 0.2×	216 1.9×	26	929
Cristina Migliore Italy	16	755 0.9×	285 1.1×	177 0.7×	25 0.2×	109 0.9×	22	1.2k
Ming‐Chih Crouthamel United States	9	526 0.6×	266 1.0×	264 1.1×	244 1.7×	48 0.4×	10	953

Countries citing papers authored by Rana Anjum

Since Specialization

Citations

This map shows the geographic impact of Rana Anjum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rana Anjum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rana Anjum more than expected).

Fields of papers citing papers by Rana Anjum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rana Anjum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rana Anjum. The network helps show where Rana Anjum may publish in the future.

Co-authorship network of co-authors of Rana Anjum

This figure shows the co-authorship network connecting the top 25 collaborators of Rana Anjum. A scholar is included among the top collaborators of Rana Anjum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rana Anjum. Rana Anjum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cassier, Philippe A., Giuseppe Curigliano, Gennaro Daniele, et al.. (2025). A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.. Journal of Clinical Oncology. 43(4_suppl).

Shore, Neal D., Begoña Mellado, Satish Shah, et al.. (2021). A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 39(6_suppl). 85–85. 3 indexed citations

Fizazi, Karim, Daniel J. George, Maria De Santis, et al.. (2021). A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).. Journal of Clinical Oncology. 39(6_suppl). TPS178–TPS178. 24 indexed citations

Reddy, Venkatesh Pilla, Rana Anjum, Michael Grondine, et al.. (2020). The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST. Clinical Cancer Research. 26(14). 3751–3759. 9 indexed citations

Jones, Rhys D.O., Alexandra Borodovsky, Maryann San Martin, et al.. (2020). A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity. British Journal of Pharmacology. 178(3). 600–613. 6 indexed citations

Degorce, Sébastien L., Rana Anjum, Andrew Bloecher, et al.. (2019). Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88^L265P Mutant Diffuse Large B Cell Lymphoma. Journal of Medicinal Chemistry. 62(21). 9918–9930. 17 indexed citations

Reddy, Venkatesh Pilla, Aaron Smith, Michael Grondine, Rana Anjum, & Rhys D.O. Jones. (2019). Abstract 1328: Exploring the pharmacokinetic-pharmacodynamic relationships of AZD3229, a novel and selective inhibitor of cKIT, in a range of mouse xenograft models of gastrointestinal stromal tumors. 1328–1328. 1 indexed citations

Degorce, Sébastien L., Rana Anjum, Keith Dillman, et al.. (2018). Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. Bioorganic & Medicinal Chemistry. 26(4). 913–924. 15 indexed citations

Tiret, Brice, Adam Autry, Ilwoo Park, et al.. (2017). EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS. Neuro-Oncology. 19(suppl_6). vi88–vi88. 1 indexed citations

10.

Geng, Huimin, Cigall Kadoch, Ming‐Chi Lu, et al.. (2016). Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. Blood. 128(22). 777–777. 2 indexed citations

11.

Garner, Andrew P., Joseph M. Gozgit, Rana Anjum, et al.. (2014). Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research. 20(22). 5745–5755. 123 indexed citations

12.

Anjum, Rana, Sadanand Vodala, Anna Kohlmann, Victor M. Rivera, & Andrew P. Garner. (2013). Abstract A98: An in vitro mutagenesis screen identifies L1951R and G2032R as drug-resistant mutants of CD74-ROS1.. Molecular Cancer Therapeutics. 12(11_Supplement). A98–A98. 1 indexed citations

13.

Squillace, Rachel M., Rana Anjum, David F. Miller, et al.. (2013). Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.. Cancer Research. 73(8_Supplement). 5655–5655. 31 indexed citations

14.

Heinrich, Michael C., Jonathan A. Fletcher, Rana Anjum, et al.. (2013). Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 31(15_suppl). 10509–10509. 1 indexed citations

15.

Anjum, Rana, et al.. (2012). 164 The Dual ALK/EGFR Inhibitor AP26113 Also Potently Inhibits. European Journal of Cancer. 48. 50–50. 2 indexed citations

16.

Rivera, Victor M., Frank Wang, Rana Anjum, et al.. (2012). Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Research. 72(8_Supplement). 1794–1794. 36 indexed citations

17.

Zhang, Sen, Frank Wang, Jeffrey Keats, et al.. (2010). Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research. 70(8_Supplement). LB–298. 44 indexed citations

18.

Kubota, Kazuishi, Rana Anjum, Yonghao Yu, et al.. (2009). Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nature Biotechnology. 27(10). 933–940. 89 indexed citations

19.

Roux, Philippe P., Bryan A. Ballif, Rana Anjum, Steven P. Gygi, & John Blenis. (2004). Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National Academy of Sciences. 101(37). 13489–13494. 611 indexed citations breakdown →

20.

Tee, Andrew R., Rana Anjum, & John Blenis. (2003). Inactivation of the Tuberous Sclerosis Complex-1 and -2 Gene Products Occurs by Phosphoinositide 3-Kinase/Akt-dependent and -independent Phosphorylation of Tuberin. Journal of Biological Chemistry. 278(39). 37288–37296. 173 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact